A biopharmaceutical company focused on cancer
Invectys Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. It was founded in 2010 by two veterans from the Institut Pasteur, based on technology they developed within the prestigious organization.
Invectys develops a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients. This allows virtually all cancers to be targeted. Invectys focuses its efforts on a highly prevalent tumor antigen : the HLA-G immune checkpoint, expressed in over 50% of cancers and critical to protecting the tumor against the host’s immune system. Invectys has created its HLA-G technological platforms to exploit the potential of this highly specific antigen.
Its lead product is IVS-3001, an anti-HLA-G CAR-T product currently in clinical Phase 1/2a in solid tumors.
Winning the CPRIT Award in November 2020, Invectys has raised more than $60 million. It is backed by French and international private investors and has received financial grants from the French state.
Invectys highlights & achievements
- An advanced pipeline exploiting several technologies an innovative HLA-G platform with both MAb and CAR-T potential
- Potential in multiple cancers :
- Multiple avenues for combination studies
- Unique prophylactic potential in early-stage and rapid-progression malignancies
- Multiple opportunities for partnership with pharma companies
- Strong IP (14 patents filed)
- Historic shareholder support
- Talented and seasoned team, supported by a strong Scientific Advisory Board
